Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer.

BACKGROUND Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). We evaluated the usefulness of plasma proGRP level as a tumor marker for diagnosis and treatment monitoring in patients with SCLC. METHODS Plasma samples were collected prospectively from 452 [212 non-small cell lung cancer (NSCLC), 105 SCLC, and 135 other diseases] patients who visited the hospital for tissue diagnosis. Plasma proGRP levels were measured using a two-step automated immunoassay. RESULTS The median proGRP level was significantly higher in patients with SCLC (892.7 pg/mL) than those with NSCLC (32.6 pg/mL, P<0.001) and other diseases (26.6 pg/mL, P<0.001). At cutoff level of 63 pg/mL, proGRP shows 85.7% sensitivity, 90.2% specificity, 72.5% positive predictive value and 95.4% negative predictive value in patients with SCLC. The area under the curve values were 0.93 for distinguishing SCLC from NSCLC, and 0.943 for distinguishing SCLC from the other conditions. Median proGRP level was higher in extensive disease (1,055.2 pg/mL) than limited disease (253.8 pg/mL, P=0.005). Median OS was significantly shorter in patients with extensive disease (6.0±0.7 months) than limited disease (12.7±4.5 months, P<0.01). Among the 39 patients with SCLC who were followed, the median proGRP levels of the 23 responders decreased after chemotherapy (P<0.001). CONCLUSIONS Plasma proGRP level could be a useful diagnostic and therapeutic monitoring biomarker for patients with SCLC and the initial level may help with SCLC tumor staging.

[1]  J. Park,et al.  Epidemiology of Lung Cancer in Korea: Recent Trends , 2016, Tuberculosis and respiratory diseases.

[2]  M. Perelman,et al.  New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer , 2016, British Journal of Cancer.

[3]  Hyunsoon Cho,et al.  Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015 , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[4]  L. Qiu,et al.  Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[5]  Rafael Rosell,et al.  Genetics and biomarkers in personalisation of lung cancer treatment , 2013, The Lancet.

[6]  D. Beer,et al.  Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. , 2013, Thoracic surgery clinics.

[7]  Chu Chen,et al.  Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis , 2011, Clinical chemistry and laboratory medicine.

[8]  Youngchul Kim,et al.  Plasma proGRP Concentration is Sensitive and Specific for Discriminating Small Cell Lung Cancer from Nonmalignant Conditions or Non-small Cell Lung Cancer , 2011, Journal of Korean medical science.

[9]  R. Molina,et al.  Diagnostic relevance of circulating biomarkers in patients with lung cancer. , 2010, Cancer biomarkers : section A of Disease markers.

[10]  Hojoong Kim,et al.  Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry Study. , 2009, Lung cancer.

[11]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[12]  K. Feldmann,et al.  Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[13]  J. Kulpa,et al.  ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. , 2008, Anticancer research.

[14]  G. Beligere,et al.  Stability of Pro-Gastrin-Releasing Peptide in Serum versus Plasma , 2008, Tumor Biology.

[15]  G. Baldwin,et al.  Synthesis, expression and biological activity of the prohormone for gastrin releasing peptide (ProGRP). , 2006, Endocrinology.

[16]  J. Slodkowska,et al.  Neuroendocrine Phenotype of Non-Small Cell Lung Carcinoma: Immunohistological Evaluation and Biochemical Study , 2005, The International journal of biological markers.

[17]  N. Viñolas,et al.  Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. , 2005, Anticancer research.

[18]  R. Molina,et al.  ProGRP: a new biomarker for small cell lung cancer. , 2004, Clinical biochemistry.

[19]  N. Viñolas,et al.  Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases , 2004, Tumor Biology.

[20]  M. Higashiyama,et al.  Demonstration and Diagnostic Significance of Pro-Gastrin-Releasing Peptide in Medullary Thyroid Carcinoma , 2000, Oncology.

[21]  H. Ohmatsu,et al.  Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. , 2000, Lung cancer.

[22]  N. Sunaga,et al.  Serum Pro-Gastrin-Releasing Peptide Is a Useful Marker for Treatment Monitoring and Survival in Small-Cell Lung Cancer , 1999, Oncology.

[23]  H. Dienemann,et al.  Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas. , 1999, Anticancer research.

[24]  H. Nakahama,et al.  CYFRA 21‐1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients , 1998, Respirology.

[25]  K. Eguchi,et al.  Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M. Fukuoka,et al.  Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. , 1996, British Journal of Cancer.

[27]  N. Maki,et al.  Enzyme‐linked Immunosorbent Assay of Pro‐gastrin‐releasing Peptide for Small Cell Lung Cancer Patients in Comparison with Neuron‐specific Enolase Measurement , 1995, Japanese journal of cancer research : Gann.

[28]  K. Yamaguchi,et al.  Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. , 1994, Cancer research.

[29]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.

[30]  N. Yanaihara,et al.  Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. , 1983, Cancer research.